How Many Drugs are in Our Drinking Water?

We are drinking WHAT?

” Thanks to the chemical, agricultural and pharmaceutical industries, and antiquated water systems, people all over the world are imbibing a witch’s brew of drugs and chemicals often without realizing it.

Associated Press reported that:

  • Epilepsy and anxiety drugs were found in Southern California water.
  • Heart and epilepsy drugs were found in Northern New Jersey water.
  • An antibiotic was found in Tucson drinking water.
  • A sex hormone was found in San Francisco drinking water. “

Read “Drugs in the Drinking Water? Don’t Ask and Officials Won’t Tell”, Truthout, 21 March, 2016.

Public drinking water by Eric Parker.

Martha Rosenberg, Organic Consumers Association News Analysis, explains:

  • Aren’t Drugs Filtered Out?
  • Fish on Hormones
  • Fish on Psychoactive Drugs
  • Big Ag Contaminants

Are autism genes in all of us?

Genetic risk for autism spectrum disorders and neuropsychiatric variation in the general population

New light has been shed on the genetic relationship between autistic spectrum disorders (ASD) and ASD-related traits in the wider population, by a team of international researchers including academics from the University of Bristol, the Broad Institute of Harvard and MIT, and Massachusetts General Hospital (MGH).


Almost all genetic risk factors for autism spectrum disorders (ASDs) can be found in the general population, but the effects of this risk are unclear in people not ascertained for neuropsychiatric symptoms.

Using several large ASD consortium and population-based resources (total n > 38,000), we find genome-wide genetic links between ASDs and typical variation in social behavior and adaptive functioning.

Autism genes are in all of us, new research reveals, University of Bristol, 21 March 2016.

This finding is evidenced through both LD score correlation and de novo variant analysis, indicating that multiple types of genetic risk for ASDs influence a continuum of behavioral and developmental traits, the severe tail of which can result in diagnosis with an ASD or other neuropsychiatric disorder.

A continuum model should inform the design and interpretation of studies of neuropsychiatric disease biology.

Premature mortality risk about 2.5 times higher in autism spectrum disorder

Autism: early death risk a ‘hidden crisis’


A registry study conducted at Karolinska Institutet shows that the risk of premature death is about 2.5 times higher for people with autism spectrum disorder than for the rest of the population.

Mortality has been suggested to be increased in autism spectrum disorder (ASD).

To examine both all-cause and cause-specific mortality in ASD, as well as investigate moderating role of gender and intellectual ability.

Odds ratios (ORs) were calculated for a population-based cohort of ASD probands (n = 27 122, diagnosed between 1987 and 2009) compared with gender-, age- and county of residence-matched controls (n = 2 672 185).

People with autism run a higher risk of premature death, Karolinska Institutet, 21 March 2016.

During the observed period, 24 358 (0.91%) individuals in the general population died, whereas the corresponding figure for individuals with ASD was 706 (2.60%; OR = 2.56; 95% CI 2.38–2.76). Cause-specific analyses showed elevated mortality in ASD for almost all analysed diagnostic categories. Mortality and patterns for cause-specific mortality were partly moderated by gender and general intellectual ability.

Premature mortality was markedly increased in ASD owing to a multitude of medical conditions.

Stilbosol-fed carlots score high in tense competition

Eli Lilly Stilbosol’s 1959 add in the FFA National Future Farmer

stilbosol ad image
Stilbosol patenting turned the cattle feed industry upside down in the mid 50s with its phenomenal use by farmers.
Image sources
Related posts
Related books
More DES DiEthylStilbestrol Resources

Prescribing antibiotics to children in the first years of their life…

Prof. Michael Borg’s warning against prescribing antibiotics to children

” There are already numerous factors contributing to asthma and obesity, such as genes and environment, which we have no control over. What we do have control over is antibiotic use so let’s do something about it.

We are becoming more and more aware of the importance that the microbiome – the trillions of ‘friendly’ bacteria in the human body – plays in the development of the body, especially in early ages.

It would appear that the more antibiotics are administered, especially to children, the greater the risk of disrupting these bacteria in the gut with potential repercussions.”

Warning against prescribing antibiotics to children, timesofmalta, March 7, 2016.

said Prof. Michael Borg, head of the National Antibiotic Committee in Malta.

Les prix très élevés des nouveaux médicaments : quelle logique?

Pourquoi les médicaments sont-ils si chers?
La dérive d’un modèle d’affaires

Cet article publie le texte de l’intervention prononcée par Marc-André Gagnon, professeur adjoint en politique publique à l’université Carleton (Ottawa, Canada), lors de la conférence-débat « Prix des nouveaux médicaments : quelle logique? », organisée dans le cadre de la Pilule d’Or.

  • Le prix des médicaments n’est pas lié à leur coût en recherche et développement.
  • Du modèle d’affaires des “blockbusters” à celui des”nichebusters”.
  • Les “nichebusters” ou quand tous veulent devenir “orphelin”.
  • En somme : les “nichebusters”, un nouveau modèle d’affaires s’avérant aussi être une impasse.

Pourquoi les médicaments sont-ils si chers? La dérive d’un modèle d’affaires, prescrire, février 2015.

Sur le même sujet

First National Standards for Prescribing Opioids for Chronic Pain

C.D.C. Painkiller Guidelines Aim to Reduce Addiction Risk

In an effort to curb what many consider the worst public health drug crisis in decades, the Centers for Disease Control and Prevention published the first national standards for opioids (prescription painkillers), recommending that doctors try pain relievers like ibuprofen before prescribing the highly addictive drugs, and that they give most patients only a limited supply.


C.D.C. Painkiller Guidelines Aim to Reduce Addiction Risk, nytimes, MARCH 15, 2016.
Pain killers image Gary H.

Primary care clinicians find managing chronic pain challenging. Evidence of long-term efficacy of opioids for chronic pain is limited. Opioid use is associated with serious risks, including opioid use disorder and overdose.

To provide recommendations about opioid prescribing for primary care clinicians treating adult patients with chronic pain outside of active cancer treatment, palliative care, and end-of-life care.

The Centers for Disease Control and Prevention (CDC) updated a 2014 systematic review on effectiveness and risks of opioids and conducted a supplemental review on benefits and harms, values and preferences, and costs. CDC used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework to assess evidence type and determine the recommendation category.

Evidence Synthesis
Evidence consisted of observational studies or randomized clinical trials with notable limitations, characterized as low quality using GRADE methodology. Meta-analysis was not attempted due to the limited number of studies, variability in study designs and clinical heterogeneity, and methodological shortcomings of studies. No study evaluated long-term (≥1 year) benefit of opioids for chronic pain. Opioids were associated with increased risks, including opioid use disorder, overdose, and death, with dose-dependent effects.

There are 12 recommendations.

  1. Of primary importance, nonopioid therapy is preferred for treatment of chronic pain.
  2. Opioids should be used only when benefits for pain and function are expected to outweigh risks.
  3. Before starting opioids, clinicians should
    1. establish treatment goals with patients
    2. and consider how opioids will be discontinued if benefits do not outweigh risks.
  4. When opioids are used, clinicians should
    1. prescribe the lowest effective dosage,
    2. carefully reassess benefits and risks when considering increasing dosage to 50 morphine milligram equivalents or more per day,
    3. and avoid concurrent opioids and benzodiazepines whenever possible.
  5. Clinicians should
    1. evaluate benefits and harms of continued opioid therapy with patients every 3 months or more frequently
    2. and review prescription drug monitoring program data, when available, for high-risk combinations or dosages.
  6. For patients with opioid use disorder, clinicians should offer or arrange evidence-based treatment, such as medication-assisted treatment with buprenorphine or methadone.

CDC Guideline for Prescribing Opioids for Chronic Pain – United States, 2016, JAMA, doi:10.1001/jama.2016.1464, March 15, 2016.

Conclusions and Relevance
The guideline is intended to improve communication about benefits and risks of opioids for chronic pain, improve safety and effectiveness of pain treatment, and reduce risks associated with long-term opioid therapy.

Enjoying outdoors and breathing fresh air in 2016

Call for a pesticide-free Spring! Join us!

The Pesticide Action Week is an annual and international event, open to everyone, with the aim to promote alternatives to pesticides. The campaign takes place during the first ten days of every spring (20th-30th of march) when usually the spreading of pesticides resumes.

The public is invited to get better informed about the sanitary and environmental challenges caused by pesticides and learn more about possible alternatives to pesticides by taking part in one of the hundreds of organised activities: conferences, panel discussions, film showings, workshops, open days at organic farms, information stands, exhibitions, shows…

The goals of this event are:

Call for a pesticide-free Spring!
Pesticide Action Week,
20th-30th of march.

  • Raising awareness on the health and environment risks of synthetic pesticides
  • Highlighting and promoting alternative solutions
  • Building a global grassroots movement for a pesticide-free world

More Information

Do doctors who get more pharma $$ prescribe more brand-name drugs? You bet they do

The more money doctors get from pharma, the more brand-name drugs they tend to prescribe…

A ProPublica analysis has found for the first time that doctors who receive payments from the medical industry do indeed tend to prescribe drugs differently than their colleagues who don’t. And the more money they receive, on average, the more brand-name medications they prescribe.

ProPublica matched records on payments from pharmaceutical and medical device makers in 2014 with corresponding data on doctors’ medication choices in Medicare’s prescription drug program.

Matching Industry Payments to Medicare Prescribing Patterns: An Analysis, static.propublica, March 2016.

Doctors who got money from drug and device makers—even just a meal– prescribed a higher percentage of brand-name drugs overall than doctors who didn’t, our analysis showed. Indeed, doctors who received industry payments were two to three times as likely to prescribe brand-name drugs at exceptionally high rates as others in their specialty.

Doctors who received more than $5,000 from companies in 2014 typically had the highest brand-name prescribing percentages. Among internists who received no payments, for example, the average brand-name prescribing rate was about 20 percent, compared to about 30 percent for those who received more than $5,000.

Continue reading Now There’s Proof: Docs Who Get Company Cash Tend to Prescribe More Brand-Name Meds, by Charles Ornstein, Ryann Grochowski Jones and Mike Tigas, on ProPublica, March 17, 2016.

Read Dollars for Docs ; How Industry Dollars Reach Your Doctors, projects.propublica, Updated March 17, 2016.